

01-07-03

PTO/SB/29 (10-00)

Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

JAN 07 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CONTINUED PROSECUTION APPLICATION (CPA)
REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing.
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

#24
R Harmon
1/30/04

Address to: Assistant Commissioner for Patents Box CPA Washington, DC 20231	<input type="checkbox"/> CHECK BOX, If applicable: <input type="checkbox"/> DUPPLICATE
---	---

Attorney Docket No. of Prior Application 1059-007	First Named Inventor Barry Libin
Examiner Name Rose, S.	
Group Art Unit 1614	
Express Mail Label No. EV208004145US	

This is a request for a continuation or divisional application under 37 CFR 1.53(d),
 (continued prosecution application (CPA)) of prior application number 09 / 224,781,
 filed on January 4, 1999, entitled Method of Preventing and treating Mucosal and dermal conditions

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application. See "Request for Continued Examination Practice changes to and Provisional Application Practice," Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office (Apr. 11, 2000).

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

1. Enter the unentered amendment previously filed on _____ under 37 CFR 1.116 in the prior nonprovisional application.
2. A preliminary amendment is enclosed.
3. This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
 - a. **DELETE** the following inventor(s) named in the prior nonprovisional application:
.....
 - b. The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
5. Information Disclosure Statement (IDS) is enclosed:
 - a. PTO-1449
 - b. Copies of IDS Citations

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box CPA, Washington, DC 20231.

01/08/2003 A00HDAF1 00000160 09224781

01 FC:2006
02 FC:2251375.00 DP
55.00 DP

RECEIVED
JAN 09 2003
TECH CENTER 1600/2900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c) or (j))	14 -20* =		x \$ _____ =	\$
	INDEPENDENT CLAIMS (37 CFR 1.16(b) or (i))	2 -3** =		x \$ _____ =	
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+ \$ _____ =	
				BASIC FEE (37 CFR 1.16)	750.00
				Total of above Calculations =	750.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.27).				375.00
	* Reissue claims in excess of 20 and over original patent. ** Reissue independent claims over original patent.			TOTAL =	375.00


6. Small entity status: Applicant claims small entity status. See 37 CFR 1.27.
7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 08-1540:
- Fees required under 37 CFR 1.16.
 - Fees required under 37 CFR 1.17.
 - Fees required under 37 CFR 1.18.
8. A check in the amount of \$ 375.00 is enclosed.
9. Payment by credit card. Form PTO-2038 is attached.
10. Applicant requests suspension of action under 37 CFR 1.103(b) for a period of _____ months (not to exceed 3 months) and the fee under 37 CFR 1.17(i) is enclosed.
11. New Attorney Docket Number, if desired
[Prior application Attorney Docket Number will carryover to this CPA unless a new Attorney Docket Number has been provided herein.]
12. a. Receipt For Facsimile Transmitted CPA (PTO/SB/29A)
b. Return Receipt Postcard (Should be specifically itemized, See MPEP 503)
13. Other: Petition for Extension of Time with Check for \$55.00

NOTE: *The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.*

14. NEW CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here)		<input type="checkbox"/> or <input type="checkbox"/> New correspondence address below
Name	James V. Costigan HEDMAN & COSTIGAN, P.C.		
Address	1185 Avenues of the Americas, Suite 2003		
City	New York	State	NY
Country	USA	Telephone	212-302-8989
		Zip Code	10036
		Fax	212-302-8998

15. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print /Type)	James V. Costigan
Signature	
Registration No. (Attorney/Agent)	25,669
Date	January 6, 2003

O P E J C 81
JAN 06 2003
TRADEMARK OFFICE
Docket No.: 1059-007

IN THE UNITED STATES PATENT AND TRADEMARK
PATENT OPERATION

In re Application of:

Barry Libin

Serial No.: 09/224,781

Filed: January 4, 1999

For: METHOD OF PREVENTING AND TREATING MUCOSAL AND DERMAL
CONDITIONS

)
) Group Art Unit: 1614
)
) Examiner: Rose, S.K.
)
)

25/c
K. Karmor
1/30/04
RECEIVED
JAN 09 2003
TECH CENTER 1600/2900

New York, NY 10036
January 6, 2003

Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

This Amendment is being filed prior to examination of
the Request for a Continuing Prosecution Application. Kindly
amend the above identified application as follows:

IN THE CLAIMS

Kindly amend claims 1 and 27-30 as follows:

C1
1. (twice amended) A method of treating fungal infections, said
method comprising contacting the affected diseased sites with an
effective amount of a composition which comprises a combination
of triclosan and a cationic antimicrobial compound.

C2
27. (amended) A method of treating fungal infections as defined
in claim 1 wherein the cationic agent is selected from the group
consisting of chlorhexidine, cetylpyridium chloride, benzalkonium
chloride, benzethonium chloride, methylbenzethonium chloride and
domiphen bromide.

28. (amended) A method of treating fungal infections as defined
in claim 1 wherein the cationic agent is cetylpyridinium